New study cites increased heart risk with Vioxx

08/26/2004 | NYTimes.com

The FDA-financed study indicates Merck's Vioxx arthritis drug is 50% more likely to cause heart attacks and sudden cardiac death than Pfizer's Celebrex. The study also found the patient risk associated with the highest recommended daily dosage of Vioxx was three times higher than for patients not taking standard painkillers. A Merck spokeswoman said the "observational" nature of the study has limitations and that several smaller Merck trials showed no greater risk of heart attack for Vioxx than Celebrex.

View Full Article in:

NYTimes.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC